Abstract
Molecular associations between the cannabinoid system and estrogens have recently been discovered. This research field is particularly interesting because it could lead to new pharmacotherapeutic approaches, especially in diseases where both molecular systems contribute to the pathophysiology. This paper presents an overview of the role of the cannabinoid system and estrogens in osteoporosis, atherosclerosis and cancer, and discusses the potential benefits of the modulating both systems in the pharmacotherapy of these diseases.
 Although an extensive literature review points to likely interactions between the cannabinoid system and estrogens, appropriate molecular studies have not yet been carried out. Our recent results in primary human osteoblasts are the first to demonstrate a possible interaction between the two systems at a molecular level.
 Further studies are needed to carefully examine molecular interactions as well as the efficacy and safety of various combinations of estrogens and cannabinoids in the pathogenesis and pharmacotherapy of osteoporosis, atherosclerosis, cancer and other common diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
